Paraoxonase (PON)1 192R allele carriage is associated with reduced risk of inflammatory bowel disease

Digestive Diseases and Sciences

Volumn 52, Issue 10, 2007, Pages 2707-2715

  Karban, Amir ^a   Hartman, Corina ^b   Eliakim, Rami ^a   Waterman, Matti ^a   Nesher, Shula ^a   Barnett Griness, Ofra ^c   Shamir, Raanan ^b  

^a Rambam Health Care Campus ^*  (Israel)

^b MEYER CHILDREN S HOSPITAL   (Israel)

^c CARMEL MEDICAL CENTER   (Israel)

Author keywords

Crohn's disease; Inflammatory bowel disease; Lactonase; Paraoxonase; Polymorphism

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ARYLDIALKYLPHOSPHATASE 1; ARYLDIALKYLPHOSPHATASE 2; DNA; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE COURSE; ENTERITIS; ETHNICITY; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC RISK; GENOTYPE PHENOTYPE CORRELATION; HAPLOTYPE; HETEROZYGOTE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLELES; ARYLDIALKYLPHOSPHATASE; CHILD; CHILD, PRESCHOOL; DNA; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INFANT; INFLAMMATORY BOWEL DISEASES; ISRAEL; JEWS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 34548514447     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-006-9700-5     Document Type: Article

References (52)

1. Bouma G, Strober W (2003) The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 3:521-533
2. Duerr RH (2003) Update on the genetics of inflammatory bowel disease. J Clin Gastroenterol 37:358-367
3. Mackness B, Mackness MI, Durrington PN, Connelly PW, Hegele RA (1996) Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol 7:69-76
4. Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN (1996) The human serum paraoxonase/ arylesterase gene (PON1) is one member of a multigene family. Genomics 33:498-507
5. Satsangi J, Parkes M, Louis E, Hashimoto L, Kato N, Welsh K, Terwilliger JD, Lathrop, GM, Bell JI, Jewell DP (1996) Two stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12. Nature Genet 14:199-202
6. Dechairo B, Dimon C, van Heel D, Mackay I, Edwards M, Scambler P, Jewell D, Cardon L, Lench N, Carey A (2001) Replication and extension studies of inflammatory bowel disease susceptibility regions confirm linkage to chromosome 6p (IBD3). Eur J Hum Genet 9:627-633
7. La Du BN, Adkins S, Kuo CL, Lipsig D (1993) Studies on human serum paraoxonase/arylesterase. Chem Biol Interact 87:25-34
8. Broomfield CA (1992) A purified recombinant organophosphorus acid anhydrase protects mice against soman. Pharmacol Toxicol 70:65-66
9. Billecke S, Draganov D, Counsell R, Stetson P, Watson C, Hsu C, La Du BN (2000) Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab Dispos 28:1335-1342
10. Teiber JF, Draganov DI, La Du BN (2003) Lactonase and lactonizing activities of human serum paraoxonase (PON1) and rabbit serum PON3. Biochem Pharmacol 66:887-896
11. Heinecke JW, Lusis AJ (1998) Paraoxonase-gene polymorphisms associated with coronary heart disease: support for the oxidative damage hypothesis? Am J Hum Genet 62:20-24
12. Mackness MI, Arrol S, Abbott C et al (1993) Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 104:129-135
13. Aviram M, Hardak E, Vaya J et al (2000) Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation 101:2510-2517
14. Fuhrman B, Volkova N, Aviram M (2002) Oxidative stress increases the expression of the CD36 scavenger receptor and the cellular uptake of oxidized low-density lipoprotein in macrophages from atherosclerotic mice: protective role of antioxidants and paraoxonase. Atherosclerosis 161:307-316
15. Watson AD, Berliner JA, Hama SY et al (1995) Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 96:2882-2891
16. Ng CJ, Wadleigh DJ, Gangopadhyay A, Hama S, Grijalva VR, Navab M, Fogelman AM, Reddy ST (2001) Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J Biol Chem 276:44444-44449
17. Draganov DI, Stetson PL, Watson CE, Billecke SS, La Du BN (2000) Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation. J Biol Chem 275:33435-33442
18. Reddy ST, Wadleigh DJ, Grijalva V, Ng C, Hama S, Gangopadhyay A, Shih DM, Lusis AJ, Navab M, Fogelman AM (2001) Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. Arterioscler Thromb Vasc Biol 21:542-547
19. Ferre N, Camps J, Fernandez-Ballart J, Arija V, Murphy MM, Ceruelo S, Biarnes E, Vilella E, Tous M, Joven J (2003) Regulation of serum paraoxonase activity by genetic, nutritional, and lifestyle factors in the general population. Clin Chem 49:1491-1497
20. Costa LG, Vitalone A, Cole TB, Furlong CE (2005) Modulation of paraoxonase (PON1) activity. Biochem Pharmacol 69:541-550
21. Cole TB, Jampsa RL, Walter BJ, Arndt TL, Richter RJ, Shih DM, Tward A, Lusis AJ, Jack RM, Costa LG, Furlong CE (2003) Expression of human paraoxonase (PON1) during development. Pharmacogenetics 13:357-364
22. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE (1993) The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 3:73-76
23. Hassett C, Richter RJ, Humbert R, Chapline C, Crabb JW, Omiecinski CJ, Furlong CE (1991) Characterization of cDNA clones encoding rabbit and human serum paraoxonase: the mature protein retains its signal sequence. Biochemistry 30:10141-10149
24. Leviev I, James RW (2000) Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler Thromb Vasc Biol 20:516-521
25. Suehiro T, Nakamura T, Inoue M, Shiinoki T, Ikeda Y, Kumon Y, Shindo M, Tanaka H, Hashimoto K (2000) A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression. Atherosclerosis 150:295-298
26. Brophy VH, Hastings MD, Clendenning JB, Richter RJ, Jarvik GP, Furlong CE (2001) Polymorphisms in the human paraoxonase (PON1) promoter. Pharmacogenetics 11:77-84
27. Wheeler JG, Keavney BD, Watkins H, Collins R, Danesh J (2004) Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. Lancet 363:689-695
28. Mochizuki H, Scherer SW, Xi T, Nickle DC, Majer M, Huizenga JJ, Tsui LC, Prochazka M (1998) Human PON2 gene at 7q21.3: cloning, multiple mRNA forms, and missense polymorphisms in the coding sequence. Gene 213:149-157
29. Sanghera DK, Aston CE, Saha N, Kamboh MI (1998) DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease. Am J Hum Genet 62:36-44
30. Hong SH, Song J, Min WK, Kim JQ (2001) Genetic variations of the paraoxonase gene in patients with coronary artery disease. Clin Biochem 34:475-481
31. Campo S, Sardo AM, Campo GM, Avenoso A, Castaldo M, D'Ascola A, Giunta E, Calatroni A, Saitta A (2004) Identification of paraoxonase 3 gene (PON3) missense mutations in a population of southern Italy. Mutat Res 546:75-80
32. Shamir R, Hartman C, Karry R, Pavlotzky E, Eliakim R, Lachter J, Suissa A, Aviram M (2005) Paraoxonases (PONs) 1, 2, and 3 are expressed in human and mouse gastrointestinal tract and in Caco-2 cell line: selective secretion of PON1 and PON2. Free Radic Biol Med 39:336-344
33. Gasche C, Schomerich J, Brynskov J et al (2000) A simple classification of Crohn's disease: report of the Working Party for the World Congress of Gastroenterology, Vienna 1998. Inflamm Bowel Dis 6:8-15
34. Karban A, Waterman M, Panhuysen CI, Pollak RD, Nesher S, Datta L, Weiss B, Suissa A, Shamir R, Brant SR, Eliakim R (2004) NOD2/CARD15 genotype and phenotype differences between Ashkenazi and Sephardic Jews with Crohn's disease. Am J Gastroenterol 99:1134-1140
35. Schaid DJ, Rowland CM, Tines DE, Jaobson RM, Poland GA (2002) Score tests for association traits with haplotypes when linkage phase is ambiguous. Am J Hum Genet 70:425-434
36. Li HL, Liu DP, Liang CC (2003) Paraoxonase gene polymorphisms, oxidative stress, and diseases. J Mol Med 81:766-779
37. Ruiz J, Blanche H, James RW, Garin MC, Vaisse C, Charpentier G, Cohen N, Morabia A, Passa P, Froguel P (1995) Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet 346:869-872
38. Odawara M, Tachi Y, Yamashita K (1997) Paraoxonase polymorphism (Gln192-Arg) is associated with coronary heart disease in Japanese noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 82:2257-2260
39. Zama T, Murata M, Matsubara Y, Kawano K, Aoki N, Yoshino H, Watanabe G, Ishikawa K, Ikeda Y (1997) A 192Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese. Arterioscler Thromb Vasc Biol 17:3565-3569
40. Ko YL, Ko YS, Wang SM, Hsu LA, Chang CJ, Chu PH, Cheng NJ, Chen WJ, Chiang CW, Lee YS (1998) The Gln-Arg 191 polymorphism of the human paraoxonase gene is not associated with the risk of coronary artery disease among Chinese in Taiwan. Atherosclerosis 141:259-264
41. Ombres D, Pannitteri G, Montali A, Candeloro A, Seccareccia F, Campagna F, Cantini R, Campa PP, Ricci G, Arca M (1998) The gln-Arg192 polymorphism of human paraoxonase gene is not associated with coronary artery disease in italian patients. Arterioscler Thromb Vasc Biol 18:1611-1616
42. Gardemann A, Philipp M, Hess K, Katz N, Tillmanns H, Haberbosch W (2000) The paraoxonase Leu-Met54 and Gln-Arg191 gene polymorphisms are not associated with the risk of coronary heart disease. Atherosclerosis 152:421-431
43. Davies HG, Richter RJ, Keifer M, Broomfield CA, Sowalla J, Furlong CE (1996) The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet 14:334-336
44. Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN (1998) Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett 423:57-60
45. Aviram M, Hardak E, Vaya J, Mahmood S, Milo S, Hoffman A, Billicke S, Draganov D, Rosenblat M (2000) Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation 101:2510-2517
46. Heijmans BT, Westendorp RG, Lagaay AM, Knook DL, Kluft C, Slagboom PE (2000) Common paraoxonase gene variants, mortality risk and fatal cardiovascular events in elderly subjects. Atherosclerosis 149:91-97
47. Leus FR, Wittekoek ME, Prins J, Kastelein JJ, Voorbij HA (2000) Paraoxonase gene polymorphisms are associated with carotid arterial wall thickness in subjects with familial hypercholesterolemia. Atherosclerosis 149:371-377
48. Draganov DI, La Du BN (2004) Pharmacogenetics of paraoxonases: a brief review. Naunyn Schmiedebergs Arch Pharmacol 369:78-88
49. Draganov DI, Teiber JF, Speelman A, Osawa Y, Sunahara R, La Du BN (2005) Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res 46:1239-1247
50. Teiber JF, Draganov DI, La Du BN (2004) Purified human serum PON1 does not protect LDL against oxidation in the in vitro assays initiated with copper or AAPH. J Lipid Res 45:2260-2268
51. Murata M, Maruyama T, Suzuki Y, Saruta T, Ikeda Y (2004) Paraoxonase 1 Gln/Arg polymorphism is associated with the risk of microangiopathy in Type 2 diabetes mellitus. Diabet Med 21:837-844
52. Chen Q, Reis SE, Kammerer CM, McNamara DM, Holubkov R, Sharaf BL, Sopko G, Pauly DF, Merz CN, Kamboh MI, WISE Study Group (2003) Association between the severity of angiographic coronary artery disease and paraoxonase gene polymorphisms in the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE) study. Am J Hum Genet 72:13-22